# Using patient-derived co-culture models of breast cancer to develop new treatment strategies targeting succinate signaling.

> **NIH NIH R21** · BETH ISRAEL DEACONESS MEDICAL CENTER · 2024 · $444,569

## Abstract

PROJECT SUMMARY/ABSTRACT:
This proposal addresses the lack of patient-derived model systems in hormone receptor positive (HR+) breast
cancer, and also the lack of ethnically representative models of breast cancer. The majority of newly diagnosed
breast cancers (>70%) are HR+, and two-thirds of the estimated 42,690 breast cancer deaths will be from HR+
breast cancer. Recurrent HR+ breast cancer has been difficult to study given the prolonged clinical course and
the lack of appropriate patient-derived model systems. These models have been difficult to derive and grow in
the past, with low take-rate (~10-20%), and the models losing their HR expression over time. In addition, tumor
extrinsic factors such as cancer-associated fibroblasts (CAFs) that significantly impact tumor biology and therapy
responses, are rarely incorporated in studies or models of HR+ disease.
 Therefore, to address this gap, we set out to develop more representative models of recurrent and
relapsed HR+ breast cancers, and to incorporate elements of the tumor microenvironment into these models.
To achieve this, we have developed a method for deriving HR+ patient-derived model systems consisting of
both, primary patient-derived tumor organoids (PDOs) isolated from relapsed and metastatic HR+ tumors, and
matching primary cancer-associated fibroblasts (CAFs) with high take rate (~50%). These models also better
represent the patients’ ethnic and racial diversity, as ~35% of our models are from underrepresented ethnicities
(e.g., African-American, Hispanic). Using these innovative tools, we have already identified SUCNR1 as a driver
of treatment resistance in HR+ breast cancer. These data led us to our hypothesis that targeting SUCNR1, will
reverse treatment resistance observed in metastatic HR+ breast cancers, and that we can use our unique PDO
models as a pre-clinical testing platform of these novel treatment strategies.
 We propose two specific aims: Aim 1 is a more technology driven per the RFA for this R21 and will
expand the number of available metastatic and relapsed HR+ patient-derived models isolated from ethnically
diverse patient populations. In Aim 2 we will Investigate the therapeutic targeting of SUCNR1 in recurrent HR+
breast cancer using our PDO models.
 Our proposal is significant because it addresses multiple fundamental challenges in breast cancer
treatment and management, including lack of patient-derived models for HR+ breast cancer, lack of tumor
models from diverse racial backgrounds, and contribution of CAFs to resistance. Most importantly, we intend to
make these models and tools available to the whole field, therefore the impact of this research is well beyond
our proposed research.

## Key facts

- **NIH application ID:** 10947728
- **Project number:** 1R21CA292302-01
- **Recipient organization:** BETH ISRAEL DEACONESS MEDICAL CENTER
- **Principal Investigator:** Taru Eliisa Muranen
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $444,569
- **Award type:** 1
- **Project period:** 2024-06-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10947728

## Citation

> US National Institutes of Health, RePORTER application 10947728, Using patient-derived co-culture models of breast cancer to develop new treatment strategies targeting succinate signaling. (1R21CA292302-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10947728. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*